PA
SLN icon

Parallel Advisors’s Silence Therapeutics SLN Stock Holding History

Parallel Advisors’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.3K Hold
1,300
– – ﹤0.01% 2785
2026
Q1 		$6.85K Hold
1,300
– – ﹤0.01% 2918
2025
Q4 		$7.9K Hold
1,300
– – ﹤0.01% 2703
2025
Q3 		$6.75K Hold
1,300
– – ﹤0.01% 2663
2025
Q2 		$7.54K Hold
1,300
– – ﹤0.01% 2594
2025
Q1 		$3.67K Buy
+1,300
New +$6.35K ﹤0.01% 2786

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Parallel Advisors's SLN Position: Q2 2026 in Review

Parallel Advisors held its Silence Therapeutics (SLN) position steady in Q2 2026 at 1,300 shares worth $14.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2785.

Parallel Advisors first reported a position in SLN in Q1 2025 and has held it in 6 quarters since. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Parallel Advisors held 1,300 shares of Silence Therapeutics worth $14.3K as of Q2 2026.
  • Parallel Advisors left its Silence Therapeutics share count unchanged in Q2 2026.
  • Silence Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2785 holding.
  • Parallel Advisors first reported a position in Silence Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.